Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antoni Ribas

Showing results (71-80 of 467) with videos related to

Pageof 47
Sort By:
Science (New York, N.Y.)|May 7, 2016
CANCER IMMUNOLOGY. The "cancer immunogram"Christian U Blank, John B Haanen, Antoni Ribas, et al.
Cancer Prevention Research (Philadelphia, Pa.)|September 18, 2020
Disparities in Cancer Prevention in the COVID-19 EraJohn M Carethers, Rajarshi Sengupta, Rea Blakey, et al.
Trends in Immunology|January 28, 2003
Determinant spreading and tumor responses after peptide-based cancer immunotherapyAntoni Ribas, John M Timmerman, Lisa H Butterfield, et al.
Current Gene Therapy|July 12, 2002
Cancer immunotherapy using gene-modified dendritic cellsAntoni Ribas, Lisa H Butterfield, John A Glaspy, et al.
The New England Journal of Medicine|April 5, 2013
Hepatotoxicity with combination of vemurafenib and ipilimumabAntoni Ribas, F Stephen Hodi, Margaret Callahan, et al.
Annals of Surgery|August 19, 2016
Cancer Research in the 21st CenturyJames S Economou, Dennis J Slamon, Antoni Ribas, et al.
Cancer Research|May 16, 2015
Classifying Cancers Based on T-cell Infiltration and PD-L1Michele W L Teng, Shin Foong Ngiow, Antoni Ribas, et al.
Nature Reviews. Clinical Oncology|November 25, 2015
Combination cancer immunotherapies tailored to the tumour microenvironmentMark J Smyth, Shin Foong Ngiow, Antoni Ribas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2021
How Did We Get a COVID-19 Vaccine in Less Than 1 Year?E John Wherry, Elizabeth M Jaffee, Nicholas Warren, et al.
Leukemia & Lymphoma|October 24, 2017
Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHLZachary J Roberts, Marc Better, Adrian Bot, et al.
Pageof 47

Showing results (71-80 of 467) with videos related to

Sort By:
Pageof 47
Science (New York, N.Y.)|May 7, 2016
CANCER IMMUNOLOGY. The "cancer immunogram"Christian U Blank, John B Haanen, Antoni Ribas, et al.
Cancer Prevention Research (Philadelphia, Pa.)|September 18, 2020
Disparities in Cancer Prevention in the COVID-19 EraJohn M Carethers, Rajarshi Sengupta, Rea Blakey, et al.
Trends in Immunology|January 28, 2003
Determinant spreading and tumor responses after peptide-based cancer immunotherapyAntoni Ribas, John M Timmerman, Lisa H Butterfield, et al.
Current Gene Therapy|July 12, 2002
Cancer immunotherapy using gene-modified dendritic cellsAntoni Ribas, Lisa H Butterfield, John A Glaspy, et al.
The New England Journal of Medicine|April 5, 2013
Hepatotoxicity with combination of vemurafenib and ipilimumabAntoni Ribas, F Stephen Hodi, Margaret Callahan, et al.
Annals of Surgery|August 19, 2016
Cancer Research in the 21st CenturyJames S Economou, Dennis J Slamon, Antoni Ribas, et al.
Cancer Research|May 16, 2015
Classifying Cancers Based on T-cell Infiltration and PD-L1Michele W L Teng, Shin Foong Ngiow, Antoni Ribas, et al.
Nature Reviews. Clinical Oncology|November 25, 2015
Combination cancer immunotherapies tailored to the tumour microenvironmentMark J Smyth, Shin Foong Ngiow, Antoni Ribas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2021
How Did We Get a COVID-19 Vaccine in Less Than 1 Year?E John Wherry, Elizabeth M Jaffee, Nicholas Warren, et al.
Leukemia & Lymphoma|October 24, 2017
Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHLZachary J Roberts, Marc Better, Adrian Bot, et al.
Pageof 47